IAVI

Media & Resources

Filter by

  • Type

  • Health area

  • Location

  • Topic

  • Year

  • Journal

  • Publication

  • Fact sheet & publication type

  • Clear all

Fact Sheets & Publications

MTBVAC: the only live-attenuated Mtb vaccine in development

IAVI is partnering with the Spanish biopharmaceutical company Biofabri in the advanced clinical development of the MTBVAC vaccine candidate to see if it prevents TB disease in infants, adolescents, and adults. MTBVAC is the only live, attenuated vaccine candidate derived from M.tb.

Read more

In The News

Céspedes: “HIV treatments have saved many lives”

La Tribuna de Albacete

December 2, 2023

Read more

Fact Sheets & Publications

Coronavirus vaccine program

IAVI and partners are leveraging our extensive vaccine development expertise to develop a vaccine to prevent COVID-19, with a focus on equitable global access.

Read more

Features

This World AIDS Day, celebrating community leadership

December 1, 2023

“Science, when it is inclusive, becomes a powerful tool for change,” says IAVI’s Monica Kuteesa.

Read more

Fact Sheets & Publications

ADVANCE

ADVANCE (Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic) is a 5-year cooperative agreement extended through June 2026 with the U.S. Agency for International Development (USAID), through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR).

Read more

Fact Sheets & Publications

IAVI Design and Development Lab

The IAVI Vaccine Design and Development Lab generates and develops innovative HIV and emerging infectious diseases vaccine candidates to address global public health needs.

Read more

IAVI Report

Will AI crack the code for antigens?

November 30, 2023

The scientific implications of artificial intelligence loom large. One tangible application is designing better vaccines.

Read more

Fact Sheets & Publications

Accelerating bnAbs for peri- and post-natal HIV prophylaxis: An Action Plan

This Action Plan defines key recommendations, priority activities, and resources needed to accelerate the clinical development, licensure, and availability of bnAbs for peri- and post-natal HIV prophylaxis. 

Read more